In combination w/ endocrine therapy for adjuvant treatment of adult patients w/ hormone receptor (HR) +ve, human epidermal growth factor receptor 2 (HER2) -ve, node +ve early breast cancer at high risk of recurrence. Treatment of women w/ HR +ve, HER2 -ve locally advanced or metastatic breast cancer in combination w/ an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.
150 mg bd, in combination w/ endocrine therapy. Patient w/ severe hepatic impairment Decrease dosing frequency to once daily. Patient concomitantly taking a strong CYP3A4 inhibitor 100 mg bd. Early breast cancer Take Verzenio continuously for 2 yr, or until disease recurrence or unacceptable toxicity. Advanced or metastatic breast cancer Take continuously as long as the patient is deriving clinical benefit from therapy or until unacceptable toxicity occurs.
Risk of neutropenia; infections; VTE; increases in ALT & AST; diarrhoea; ILD/pneumonitis. Monitor CBC prior to treatment initiation, every 2 wk for the 1st 2 mth, mthly for the next 2 mth, & as clinically indicated. Avoid concomitant use w/ CYP3A4 inducers. Patients w/ rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine. Minor influence on the ability to drive & use machines. Caution in patients w/ severe renal or hepatic impairment. Women of childbearing potential should use highly effective contraception methods (eg, double-barrier contraception) during treatment & for at least 3 wk after completing therapy. Not recommended during pregnancy & in women of child-bearing potential not using contraception. Patients receiving abemaciclib should not breastfeed. Safety & efficacy have not been established in childn & adolescents <18 yr. No data on efficacy & safety in patients w/ visceral crisis.
Sign Out
